Replies to post #8771 on Innovus Pharmaceuticals Inc. (fka INNV)

[Batermere]

Possibly, sweetstreet. Runups in "anticipation" of a SIGNIFICANT EVENT rarely last. So INNV went from .66 back down to where we are now. No surprise there. What's going to drive the SP are basic fundamentals ..... net profits on revenues produced. I think the estimates are that FlutiCare, once launched and out there being purchased, will add close to $15 million in revenues to the bottom line. I have no idea how that will translate into net profits. However, if Guidance for 2017 was set at $15 million in revenues, that number just got doubled once FlutiCare has a year of sales under its belt. Net profits will undoubtedly go up as well. Nothing happens overnight. INNV is going to have to grind it out day after day to grow into a company that hopefully will be attractive for a buyout and big PAYDAY in the future.

[kkpennies]

There was a promo.

After the run, if I remember correctly, it dropped after GlaxoSmithKline or Bayer got approval for their OTC version

[Biotech Pharmer]

The Novalere sponsored FlutiCare ANDA remains a big question. Damaj already paid Novalere ALL of the shares for it(dilutive shares, BTW) that should have been held in escrow until approval, as stated in the original deal. WHY????